741709-57-9

Usage

Uses

Used in Organic Synthesis:
Ethyl 5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)picolinate is used as a key intermediate in organic synthesis for the preparation of various complex organic compounds. Its reactivity and stability make it a versatile building block in the synthesis of pharmaceuticals, agrochemicals, and other bioactive molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, ethyl 5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)picolinate is employed as a precursor for the development of new pharmaceuticals. Its unique structure allows for the design and synthesis of novel drug candidates with potential therapeutic applications.
Used in Drug Discovery:
Ethyl 5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)picolinate is utilized in drug discovery as a starting material for the synthesis of potential drug candidates. Its reactivity in various chemical reactions enables the generation of diverse chemical libraries, which can be screened for biological activity and further optimized for improved potency and selectivity.
Used in Bioactive Molecule Development:
This boronic ester derivative is also used in the development of bioactive molecules with potential applications in various industries, such as pharmaceuticals, agrochemicals, and materials science. Its unique properties and reactivity contribute to the discovery of new molecules with therapeutic, pesticidal, or other beneficial properties.

Upstream product

• 2524-52-9 ethyl-2-picolinate 
• 73183-34-3 bis(pinacol)diborane 
• 77199-09-8 5-bromo-pyridine-2-carboxylic acid ethyl ester 
• 624-28-2 2,5-dibromopyridine 
• 98-98-6 2-Picolinic acid 

Relevant academic research and scientific papers

TRICYCLIC COMPOUND FOR BROMODOMAIN-CONTAINING PROTEIN INHIBITOR AND PREPARATION, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF

The present applicationpresent application relates to a compound represented by Formula (III) or a pharmaceutically acceptable salt, solvent compound, active metabolite, crystal polymorph, ester, isomer, or prodrug thereof. The application further provides a pharmaceutical composition comprising the compound represented by Formula (III) and a use thereof for preparing a bromodomain inhibitor for preventing or treating various diseases, such as inflammation and cancer, related to the bromodomain.

BIPYRIDYL COMPOUND

There are provided a compound capable of being a novel ligand allowing regioselective borylation to be performed in the aromatic borylation reaction, and a catalyst using the same compound. There is provided a bipyridyl compound represented by a general f

Noncovalent Interactions in Ir-Catalyzed C-H Activation: L-Shaped Ligand for Para-Selective Borylation of Aromatic Esters

An efficient strategy for the para-selective borylation of aromatic esters is described. For achieving high para-selectivity, a new catalytic system has been developed modifying the core structure of the bipyridine. It has been proposed that the L-shaped ligand is essential to recognize the functionality of the oxygen atom of the ester carbonyl group via noncovalent interaction, which provides an unprecedented controlling factor for para-selective C-H activation/borylation.

Fusaric acid and analogues as Gram-negative bacterial quorum sensing inhibitors

Taking advantage of microwave-assisted synthesis, efficient and expedite procedures for preparation of a library of fusaric acid and 39 analogues are reported. The fusaric acid analogues were tested in cell-based screening assays for inhibition of the las and rhl quorum sensing system in Pseudomonas aeruginosa and the lux quorum sensing system in Vibrio fischeri. Eight of the 40 compounds in the library including fusaric acid inhibited lux quorum sensing and one compound inhibited activity of the las quorum sensing system. To our delight, none of the compounds showed growth inhibitory effects in the tested concentration ranges.

A meta-selective C-H borylation directed by a secondary interaction between ligand and substrate

Regioselective C-H bond transformations are potentially the most efficient method for the synthesis of organic molecules. However, the presence of many C-H bonds in organic molecules and the high activation barrier for these reactions make these transformations difficult. Directing groups in the reaction substrate are often used to control regioselectivity, which has been especially successful for the ortho-selective functionalization of aromatic substrates. Here, we describe an iridium-catalysed meta-selective C-H borylation of aromatic compounds using a newly designed catalytic system. The bipyridine-derived ligand that binds iridium contains a pendant urea moiety. A secondary interaction between this urea and a hydrogen-bond acceptor in the substrate places the iridium in close proximity to the meta-C-H bond and thus controls the regioselectivity. 1 H NMR studies and control experiments support the participation of hydrogen bonds in inducing regioselectivity. Reversible direction of the catalyst through hydrogen bonds is a versatile concept for regioselective C-H transformations.

HETEROCYCLIC COMPOUND

The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.